Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.

Löffler MW, Kowalewski DJ, Backert L, Bernhardt J, Adam P, Schuster H, Dengler F, Backes D, Kopp HG, Beckert S, Wagner S, Königsrainer I, Kohlbacher O, Kanz L, Königsrainer A, Rammensee HG, Stevanović S, Haen SP.

Cancer Res. 2018 Aug 15;78(16):4627-4641. doi: 10.1158/0008-5472.CAN-17-1745. Epub 2018 May 22.

2.

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS.

Leukemia. 2015 Mar;29(3):647-59. doi: 10.1038/leu.2014.233. Epub 2014 Aug 5. Erratum in: Leukemia. 2016 Apr;30(4):1003-4.

PMID:
25092142
3.

Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.

Mommen GP, Marino F, Meiring HD, Poelen MC, van Gaans-van den Brink JA, Mohammed S, Heck AJ, van Els CA.

Mol Cell Proteomics. 2016 Apr;15(4):1412-23. doi: 10.1074/mcp.M115.055780. Epub 2016 Jan 13.

4.

Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Freudenmann LK, Marcu A, Stevanović S.

Immunology. 2018 Jul;154(3):331-345. doi: 10.1111/imm.12936. Epub 2018 May 8. Review.

5.

The human leukocyte antigen-presented ligandome of B lymphocytes.

Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA.

Mol Cell Proteomics. 2013 Jul;12(7):1829-43. doi: 10.1074/mcp.M112.024810. Epub 2013 Mar 12.

6.

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS.

Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10.

PMID:
30530751
7.

HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.

Kochin V, Kanaseki T, Tokita S, Miyamoto S, Shionoya Y, Kikuchi Y, Morooka D, Hirohashi Y, Tsukahara T, Watanabe K, Toji S, Kokai Y, Sato N, Torigoe T.

Oncoimmunology. 2017 Feb 16;6(4):e1293214. doi: 10.1080/2162402X.2017.1293214. eCollection 2017.

8.

Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.

Marcilla M, Alpízar A, Lombardía M, Ramos-Fernandez A, Ramos M, Albar JP.

Mol Cell Proteomics. 2014 Feb;13(2):462-74. doi: 10.1074/mcp.M113.034314. Epub 2013 Dec 23.

9.

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112. Epub 2014 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6254-6. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6258-60.

10.

Pre-fractionation Extends but also Creates a Bias in the Detectable HLA Class Ι Ligandome.

Demmers LC, Heck AJR, Wu W.

J Proteome Res. 2019 Apr 5;18(4):1634-1643. doi: 10.1021/acs.jproteome.8b00821. Epub 2019 Feb 26.

11.
12.

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S, Walz JS.

Oncoimmunology. 2018 Feb 14;7(4):e1316438. doi: 10.1080/2162402X.2017.1316438. eCollection 2018.

13.

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Blood. 2015 Sep 3;126(10):1203-13. doi: 10.1182/blood-2015-04-640532. Epub 2015 Jul 2. Erratum in: Blood. 2015 Oct 22;126(17):2072-3.

14.

Analysis of the HLA class I associated peptide repertoire in a hepatocellular carcinoma cell line reveals tumor-specific peptides as putative targets for immunotherapy.

Alvarez I, Carrascal M, Canals F, Muixí L, Abián J, Jaraquemada D.

Proteomics Clin Appl. 2007 Mar;1(3):286-98. doi: 10.1002/prca.200600388.

PMID:
21136679
15.

Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.

Chornoguz O, Gapeev A, O'Neill MC, Ostrand-Rosenberg S.

Mol Cell Proteomics. 2012 Nov;11(11):1457-67. doi: 10.1074/mcp.M112.019232. Epub 2012 Aug 31.

16.

Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer.

Lee HJ, Hong CY, Jin CJ, Kim MH, Lee YK, Nguyen-Pham TN, Lee H, Park BC, Chung IJ, Kim HJ, Lee JJ.

Cell Mol Immunol. 2012 Mar;9(2):175-83. doi: 10.1038/cmi.2011.52. Epub 2012 Jan 9.

17.

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.

Löffler MW, Mohr C, Bichmann L, Freudenmann LK, Walzer M, Schroeder CM, Trautwein N, Hilke FJ, Zinser RS, Mühlenbruch L, Kowalewski DJ, Schuster H, Sturm M, Matthes J, Riess O, Czemmel S, Nahnsen S, Königsrainer I, Thiel K, Nadalin S, Beckert S, Bösmüller H, Fend F, Velic A, Maček B, Haen SP, Buonaguro L, Kohlbacher O, Stevanović S, Königsrainer A; HEPAVAC Consortium, Rammensee HG.

Genome Med. 2019 Apr 30;11(1):28. doi: 10.1186/s13073-019-0636-8.

18.

Peptides presented by HLA class I molecules in the human thymus.

Espinosa G, Collado JA, Scholz E, Mestre-Ferrer A, Kuse N, Takiguchi M, Carrascal M, Canals F, Pujol-Borrell R, Jaraquemada D, Alvarez I.

J Proteomics. 2013 Dec 6;94:23-36. doi: 10.1016/j.jprot.2013.08.023. Epub 2013 Sep 9.

PMID:
24029068
19.

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Klatt MG, Kowalewski DJ, Schuster H, Di Marco M, Hennenlotter J, Stenzl A, Rammensee HG, Stevanović S.

Oncoimmunology. 2016 Jun 30;5(8):e1204504. doi: 10.1080/2162402X.2016.1204504. eCollection 2016 Aug.

20.

HLA ligand profiles of primary renal cell carcinoma maintained in metastases.

Stickel JS, Weinzierl AO, Hillen N, Drews O, Schuler MM, Hennenlotter J, Wernet D, Müller CA, Stenzl A, Rammensee HG, Stevanović S.

Cancer Immunol Immunother. 2009 Sep;58(9):1407-17. doi: 10.1007/s00262-008-0655-6. Epub 2009 Feb 1.

PMID:
19184600

Supplemental Content

Support Center